CHICAGO, Oct. 11, 2013 /PRNewswire/ -- Positron
Corporation (OTCBB:POSC) is proud to announce its wholly owned
subsidiary, Manhattan Isotope Technology, has received ISO 9001
certification for the production of radioisotopes. ISO is the
International Organization for Standardization. The ISO 9001
international standard is recognized globally as the quality
management standard. With this accredited certification, Positron
joins a globally recognized consortium of companies demonstrating
excellence in a well-managed and customer-focused delivery of
products.
Positron has invested significant resources to implement a solid
quality management program essential to ensure the delivery of
quality, reliable, radioisotope products that conform to customer,
statutory, and regulatory requirements. Achieving ISO
9001:2008 certification is validation of Positron's commitment to
ensuring that our radioisotope products consistently meet product
specifications and is applied to our product development,
manufacturing, delivery, business practices and customer
satisfaction.
ISO certification is essential as Positron collaborates with
global suppliers and customers. Positron is able to represent to
its customers that its radioisotope products are manufactured under
stringent quality requirements and that our suppliers also meet
quality criteria. As the only ISO certified supplier of
strontium-82 in the United States,
Positron certifiably operates to the same quality standards as its
customers.
Suzanne Kitten, Director of
Radioisotope Operations of Positron Corporation, states, "This
certification represents an important benchmark for Positron as a
quality-committed supplier in the strontium-82 arena. Positron is
defining radioisotope production excellence; commitment to the ISO
endorsement is confirmation of our capability to produce a quality
product for the nuclear medicine industry."
"We continue to make great strides in our privatization of
strontium-82 production," stated, Jason
Kitten, Executive Director of Radioisotopes of Positron
Corporation, further states, "Our goal was not only to set the
quality stage for private production of medical radioisotopes, but
to redefine the industry's expectations. Our team brings
unique, qualified expertise along with decades of experience to
Positron's radioisotope production capabilities and achieving ISO
certification is the perfect complement to our strontium-82
product."
About Positron: Positron Corporation is a nuclear
medicine healthcare company vertically integrating all the segments
of nuclear cardiology; providing an end-to-end solution for cardiac
PET. Through proprietary PET imaging systems,
radiopharmaceuticals and radioisotopes solutions, Positron enables
healthcare providers to more accurately diagnose disease and
improve patient outcomes, while practicing cost effective medicine.
Positron's unique products, market position and approach in
securing the supply chain are substantial advantages, further
accelerating the adoption of cardiac PET and growth of nuclear
cardiology. Positron is redefining the industry. More
information about Positron is available at www.positron.com.
Forward Looking Statements: Statements in this
document contain certain forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933 and Section
21E of the Securities Exchange Act of 1934, as amended. These
statements are based on many assumptions and estimates and are not
guarantees of future performance. These statements may involve
known and unknown risks, uncertainties and other factors which may
cause the actual results, performance or achievements of Positron
Corporation to be materially different from future results,
performance or achievements expressed or implied by such
forward-looking statements. Positron assumes no obligation to
publicly update or revise these forward-looking statements for any
reason, or to update the reasons actual results could differ
materially from those anticipated in these forward-looking
statements, even if new information becomes available in the
future. Our actual results may differ materially from the
results anticipated in these forward-looking statements due to a
variety of factors, including, without limitation those set forth
as "Risk Factors" in our filings with the Securities and Exchange
Commission.
SOURCE Positron Corporation